-
EP3722426
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3722426
| EP3722426 - FACTOR VIII VARIANT-EXPRESSING VECTOR WITH INCREASED PROTEIN EXPRESSION CAPACITY [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 18.10.2024 Database last updated on 30.10.2024 | |
| Former | Request for examination was made Status updated on 11.09.2020 | ||
| Former | The international publication has been made Status updated on 15.06.2019 | Most recent event Tooltip | 18.10.2024 | Application deemed to be withdrawn | published on 20.11.2024 [2024/47] | Applicant(s) | For all designated states G&P Bioscience Co., Ltd. B-809, 401, Yangcheon-ro Gangseo-gu Seoul 07528 / KR | For all designated states Reyon Pharmaceutical Co., Ltd. 8F, 416, Yeongdong-daero Gangnam-gu Seoul 06176 / KR | [2020/43] |
| Former [2020/42] | For all designated states G&P Bioscience Co., Ltd. 517 32 Dongguk-ro Ilsandong-gu Goyang-si, Gyeonggi-do 10326 / KR | ||
| For all designated states Reyon Pharmaceutical Co., Ltd 8 Floor, KT&G Tower 416, Yeongdong-daero Gangnam-gu Seoul 06176 / KR | Inventor(s) | 01 /
HO, Seong-Hyun 305-104 63 Sinjeong-ro 11-gil Yangcheon-gu Seoul 08052 / KR | 02 /
PARK, Su Jin 303-1902 801 Ori-ro Gwangmyeong-si Gyeonggi-do 14256 / KR | [2020/42] | Representative(s) | V.O. P.O. Box 87930 2508 DH Den Haag / NL | [2020/42] | Application number, filing date | 18886810.3 | 05.12.2018 | [2020/42] | WO2018KR15333 | Priority number, date | KR20170167405 | 07.12.2017 Original published format: KR 20170167405 | [2020/42] | Filing language | KO | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019112322 | Date: | 13.06.2019 | Language: | KO | [2019/24] | Type: | A1 Application with search report | No.: | EP3722426 | Date: | 14.10.2020 | Language: | EN | [2020/42] | Search report(s) | International search report - published on: | KR | 13.06.2019 | (Supplementary) European search report - dispatched on: | EP | 24.09.2021 | Classification | IPC: | C12N15/67, C12N15/85, C12N9/10, A61K48/00, A61K38/00 | [2020/42] | CPC: |
C07K14/755 (EP,US);
C12N15/67 (EP,KR);
A61K48/00 (KR,US);
A61P7/04 (EP);
C12N15/85 (KR,US);
C12N9/1044 (KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/42] | Title | German: | FAKTOR-VIII-VARIANTE EXPRIMIERENDER VEKTOR MIT ERHÖHTER PROTEINEXPRESSIONKAPAZITÄT | [2020/42] | English: | FACTOR VIII VARIANT-EXPRESSING VECTOR WITH INCREASED PROTEIN EXPRESSION CAPACITY | [2020/42] | French: | VECTEUR EXPRIMANT UN VARIANT DU FACTEUR VIII AYANT UNE CAPACITÉ D'EXPRESSION DE LA PROTÉINE ACCRUE | [2020/42] | Entry into regional phase | 07.07.2020 | Translation filed | 07.07.2020 | National basic fee paid | 07.07.2020 | Search fee paid | 07.07.2020 | Designation fee(s) paid | 07.07.2020 | Examination fee paid | Examination procedure | 07.07.2020 | Examination requested [2020/42] | 25.03.2022 | Amendment by applicant (claims and/or description) | 02.07.2024 | Application deemed to be withdrawn, date of legal effect [2024/47] | 25.07.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2024/47] | Fees paid | Renewal fee | 22.12.2020 | Renewal fee patent year 03 | 29.12.2021 | Renewal fee patent year 04 | 25.10.2022 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 31.12.2023 | 06 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2017083762 (BAXALTA INC [US], et al) [A] 1-10 * paragraph [0010]; example 4 *; | [A]US6818439 (JOLLY DOUGLAS J [US], et al) [A] 1-10 * column 68 - column 69; sequence 45 *; | [ ] - "Human factor VIII mutant protein (des 771-1666 deletion).", Geneseq, (20050127), Database accession no. ADU47609, URL: EBI, XP002804106 [ ] * sequence . * | [ ] - "Human factor VIII mutant protein (des 779-1658 deletion).", Geneseq, (20050127), Database accession no. ADU47625, URL: EBI, XP002804107 [ ] * sequence . * | International search | [A]WO2017075619 (SPARK THERAPEUTICS INC [US]) [A] 1-10; | [A]WO2012006635 (BIOGEN IDEC HEMOPHILIA INC [US], et al) [A] 1-10; | [A] - MIAO, HONGZHI Z, "Bioengineering of coagulation factor VIII for improved secretion", Blood, (20040000), vol. 103, no. 9, doi:doi:10.1182/blood-2003-10-3591, pages 3412 - 3419, XP002452857 [A] 1-10 DOI: http://dx.doi.org/10.1182/blood-2003-10-3591 | [A] - WARD, NATALIE J, "Codon optimization of human factor VIII cDNAs leads to high-level expression", Blood, (20110000), vol. 117, no. 3, doi:doi:10.1182/blood-2010-05-282707, pages 798 - 807, XP055052195 [A] 1-10 DOI: http://dx.doi.org/10.1182/blood-2010-05-282707 | [A] - ZHANG, BIN, "LMAN1 and MCFD2 form a cargo receptor complex and interact with coagulation factor VIII in the early secretory pathway", Journal of Biological Chemistry, (20050708), vol. 280, no. 27, pages 25881 - 25886, XP055616584 [A] 1-10 DOI: http://dx.doi.org/10.1074/jbc.M502160200 | by applicant | KR101542752B | - FROKJAER, Pharmaceutical Formulation of Peptides and Proteins | - LEE Y et al., "Improved expression of vascular endothelial growth factor by naked DNA in mouse skeletal muscles: implication for gene therapy of ischemic diseases", Biochem. Biophys. Res. Commun., (20020000), vol. 272, no. 1, pages 230 - 235 |